病毒学
dna疫苗
免疫
中和抗体
免疫
抗体
免疫系统
裸DNA
抗原
冠状病毒
质粒
医学
生物
免疫学
病毒
DNA
传染病(医学专业)
2019年冠状病毒病(COVID-19)
疾病
遗传学
病理
作者
Hung‐Chun Liao,Kuan‐Yin Shen,Chung‐Hsiang Yang,Fang‐Feng Chiu,Chen-Yi Chiang,Kit Man Chai,Wan‐Chun Huang,Hui‐Min Ho,Yihua Chen,Min‐Syuan Huang,Ching‐Len Liao,Hsin‐Wei Chen,Ming‐Hsi Huang,Shih‐Jen Liu
标识
DOI:10.1016/j.omtm.2023.101169
摘要
DNA vaccines for infectious diseases and cancer have been explored for years. To date, only one DNA vaccine (ZyCoV-D) has been authorized for emergency use in India. DNA vaccines are inexpensive and long-term thermostable, however, limited by the low efficiency of intracellular delivery. The recent success of mRNA/lipid nanoparticle (LNP) technology in the coronavirus disease 2019 (COVID-19) pandemic has opened a new application for nucleic acid-based vaccines. Here, we report that plasmid encoding a trimeric spike protein with LNP delivery (pTS/LNP), similar to those in Moderna's COVID-19 vaccine, induced more effective humoral responses than naked pTS or pTS delivered via electroporation. Compared with TSmRNA/LNP, pTS/LNP immunization induced a comparable level of neutralizing antibody titers and significant T helper 1-biased immunity in mice; it also prolonged the maintenance of higher antigen-specific IgG and neutralizing antibody titers in hamsters. Importantly, pTS/LNP immunization exhibits enhanced cross-neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and protects hamsters from the challenge of SARS-CoV-2 (Wuhan strain and the Omicron BA.1 variant). This study indicates that pDNA/LNPs as a promising platform could be a next-generation vaccine technology.
科研通智能强力驱动
Strongly Powered by AbleSci AI